We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

300896:SZSEIMEIK Technology Development Co., Ltd. Class A Analysis

Data as of 2026-03-12 - not real-time

CN¥141.66

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Imeik Technology Development trades at CNY 141.66, sitting below its 20‑day (≈144.30) and 50‑day (≈144.55) simple moving averages and well under the 200‑day average (≈165.06), signaling a short‑term bearish bias. Technical indicators such as a negative MACD histogram and a neutral RSI around 47 reinforce the downside momentum, while volume has been on a decreasing trend. On the valuation side, the stock’s PE ratio of 29 exceeds the industry average of 26.7 and the DCF‑derived fair value of roughly CNY 57, suggesting the market is pricing in significant premium. However, the company boasts exceptional profitability—gross margin above 93 % and operating margin over 54 %—and a strong cash position (≈CNY 3.7 bn) with minimal debt, which underpins its resilience. The dividend yield of 3.48 % is attractive, but the payout ratio above 100 % raises concerns about sustainability. Analysts are optimistic, assigning a “buy” consensus and price targets near CNY 185‑186, implying potential upside of around 30 % if the stock can reverse its technical weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below short‑term moving averages
  • Decreasing trading volume
  • Support level near CNY 137.5 providing limited downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong profit margins and robust cash generation
  • Low debt and solid balance sheet
  • Analyst price targets indicating ~30% upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable high ROE (~19%) and ROA (~11%)
  • Growing demand for medical instrument and aesthetic products in China
  • Potential to improve revenue growth while maintaining high margins

Key Metrics & Analysis

Financial Health

Revenue Growth-21.30%
Profit Margin58.26%
P/E Ratio29.1
ROE18.99%
ROA11.33%
Debt/Equity0.47
P/B Ratio5.8
Op. Cash FlowCN¥1.5B
Free Cash FlowCN¥977.7M
Industry P/E26.7

Technical Analysis

TrendBearish
RSI47.1
SupportCN¥137.47
ResistanceCN¥158.80
MA 20CN¥144.30
MA 50CN¥144.55
MA 200CN¥165.06
MACDBearish
VolumeDecreasing
Fear & Greed Index76.38

Valuation

Fair ValueCN¥56.79
Target PriceCN¥186.16
Upside/Downside31.41%
GradeOvervalued
TypeValue
Dividend Yield3.48%

Risk Assessment

Beta0.27
Volatility32.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.